Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Onconova Therapeutic (NQ: ONTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Onconova Therapeutic

< Previous 1 2 Next >
Traws Pharma Announces New Employee Inducement Grants
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
Translational science to characterize pathways impacted by rigosertib may help to guide future clinical studies and combination treatment regimen for difficult-to-treat cancers 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Expands Leadership Team with Two Key Appointments
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Encouraging Rigosertib Data Presented at EADV as Late Breaker
Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet need 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 10, 2023 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib, the current standard-of-care 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Conference call and live webcast at 4:30 p.m. ET today 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Monday, May 15, 2023 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting
Data further characterize narazaciclib’s mechanism of action and show its anti-cancer activity comparing favorably to that of FDA-approved CDK 4/6 inhibitors 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
Conference call and live webcast at 4:30 p.m. ET today 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Thursday, March 16, 2023 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.